The hallmark of Alzheimer’s disease is the buildup of amyloid plaques in the brain. For years, clinicians have relied on this biological marker to prescribe the latest generation of anti-amyloid therapies. But there is a problem. These drugs do not work for everyone.

New research suggests the answer lies not just in plaques, but in how the brain consumes energy. A study presented at the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting found that specific metabolic patterns, visible through 18F-FDG PET imaging, can predict which patients will see their cognitive decline stabilize and which will continue to fade.

This is a potential turning point. It moves Alzheimer's care from a one-size-fits-all approach toward precision medicine.

The Diagnostic Gap

Clinical diagnosis is often imprecise. Many patients diagnosed with Alzheimer’s based on current criteria are later found to have other underlying pathologies, such as Lewy body disease or frontotemporal lobar degeneration. These conditions mimic Alzheimer’s symptoms but do not respond to anti-amyloid drugs.

"Numerous large-scale prior studies have shown that many people who meet the requirements for the clinical diagnosis of Alzheimer's disease are actually found to have other diagnoses underlying their cognitive impairment," said Amanda Rose Nguyen, a clinical fellow in nuclear medicine at UCLA.

This diagnostic confusion explains the variability in treatment success. If the disease isn't driven by amyloid, the drug is unlikely to help. It might even cause harm.

Mapping Brain Metabolism

To test if imaging could bridge this gap, researchers analyzed 124 patients considered for amyloid immunotherapy. They tracked brain metabolism using 18F-FDG PET scans, which measure glucose consumption in the brain.

The results were striking. Patients whose PET scans showed metabolic patterns consistent with Alzheimer’s disease saw their cognitive scores stabilize after one year of treatment. Patients whose scans indicated other pathologies—such as Lewy body disease or TDP-43 encephalopathy—experienced significant cognitive decline despite receiving the same therapy.

It was a clear divide. The scan acted as a filter. It separated those who could be helped from those who could not.

Why This Matters Now

Anti-amyloid therapies are expensive. They also carry risks of adverse side effects. For a patient with a non-amyloid pathology, the treatment offers no clinical benefit while exposing them to unnecessary medical burden.

"Armed with powerful brain metabolic data, physicians can provide more personalized care," Nguyen noted. By using PET imaging as a gatekeeper, doctors can spare patients from ineffective treatments. They can focus resources where they are most likely to succeed.

Key Takeaways

  • Metabolic Predictors: 18F-FDG PET scans can identify specific brain energy patterns that correlate with a positive response to anti-amyloid Alzheimer's drugs.
  • Diagnostic Accuracy: Many patients diagnosed with Alzheimer's actually have other neurodegenerative conditions that do not respond to amyloid-targeting therapies.
  • Precision Care: Using metabolic imaging allows physicians to avoid prescribing ineffective treatments, reducing both patient risk and unnecessary healthcare costs.

The Path Forward

This study, which earned the SNMMI Henry N. Wagner, Jr., Abstract of the Year, is retrospective. It is a starting point, not a final verdict. Nguyen and her team are already working on larger, high-powered analyses to confirm these findings.

By the end of the year, we should have a clearer picture of the predictive value of these metabolic patterns. For now, the message to clinicians is clear: look beyond the plaques. Comprehensive neuroimaging is no longer optional. It is essential to getting the diagnosis—and the treatment—right.

This article is for informational purposes only. Always consult a qualified healthcare professional before making any medical decisions.